HIV vaccine - PX Therapeutics

Drug Profile

HIV vaccine - PX Therapeutics

Alternative Names: EN41-FPA2 HIV; EN41-FPA2 HIV vaccine candidate - PX Therapeutics; EN41-UGR7C; EN41-UGR7C HIV vaccine candidate - PX Therapeutics; EuroNeut41 prophylactic HIV vaccine - PX Therapeutics; HIV vaccine - PX'Therapeutics

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PX Therapeutics
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in United Kingdom (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in United Kingdom (Intranasal)
  • 01 Feb 2014 PX Therapeutics completes a phase I trial of EN41-UGR7C for HIV infections (prevention; in volunteers) in United Kingdom (NCT01827397)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top